Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chronocort® Pharmacokinetics and Dose Proportionality in Healthy Volunteers
NCT03051893Phase 1Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Feb 2011
- Primary completion
- Apr 2012
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of hydrocortisone modified-release in adrenal insufficiency (AI) and congenital adrenal hyperplasia (CAH) (3 arms), sponsored by Neurocrine Biosciences. Primary endpoints: Time to Maximum Plasma Concentration at 18 hours, Maximum Plasma Concentration at 18 hours and 3 more. Started Feb 2011; status: completed.
02
Drugs
hydrocortisone modified-release
03
Conditions
adrenal insufficiency (AI)congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT03051893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03051893.